Prognostication in Pulmonary Arterial Hypertension

被引:7
作者
Agarwal, Richa [1 ,2 ]
Gomberg-Maitland, Mardi [1 ]
机构
[1] Univ Chicago, Dept Med, Cardiol Sect, Chicago, IL 60637 USA
[2] Columbia Univ, Cardiol Sect, New York Presbyterian Hosp, New York, NY USA
关键词
Pulmonary arterial hypertension; Survival; Prognostic factors; Risk prediction; BRAIN NATRIURETIC PEPTIDE; CALCIUM-CHANNEL BLOCKERS; EUROPEAN-ASSOCIATION; CLINICAL-OUTCOMES; AMERICAN-SOCIETY; HEART-FAILURE; SURVIVAL; EPOPROSTENOL; HEMODYNAMICS; PROGNOSIS;
D O I
10.1016/j.hfc.2012.04.011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Despite the advances in diagnostic and treatment strategies, and contemporary survival estimates suggesting improved outcomes, the prognosis of patients with pulmonary arterial hypertension (PAH) remains poor. To date, there is no consensus on which prognostic variables or risk prediction strategies best predict survival, at baseline and at different time points in the disease course. Even less clear is whether current prognostic variables accurately reflect disease severity and can sufficiently guide therapeutic decisions. This article reviews the most common factors used for prognostication in PAH, emphasizing that proper strategies for identifying patients at greatest risk are paramount.
引用
收藏
页码:373 / +
页数:12
相关论文
共 50 条
  • [1] Pulmonary arterial hypertension
    Uzunpinar, Aydin
    Cilingiroglu, Mehmet
    CURRENT ATHEROSCLEROSIS REPORTS, 2009, 11 (02) : 139 - 145
  • [2] Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Biomarkers in pulmonary arterial hypertension
    Minai, Omar A.
    ANNALS OF THORACIC MEDICINE, 2014, 9 (05) : 92 - 97
  • [3] Goal-oriented treatment of pulmonary arterial hypertension
    Jardim, Carlos
    Cesar Fernandes, Caio Julio
    Souza, Rogerio
    CURRENT OPINION IN PULMONARY MEDICINE, 2014, 20 (05) : 409 - 413
  • [4] Predicting Survival in Pulmonary Arterial Hypertension Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL)
    Benza, Raymond L.
    Miller, Dave P.
    Gomberg-Maitland, Mardi
    Frantz, Robert P.
    Foreman, Aimee J.
    Coffey, Christopher S.
    Frost, Adaani
    Barst, Robyn J.
    Badesch, David B.
    Elliott, C. Gregory
    Liou, Theodore G.
    McGoon, Michael D.
    CIRCULATION, 2010, 122 (02) : 164 - U138
  • [5] Hemodynamic monitoring in pulmonary arterial hypertension
    Frantz, Robert P.
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2011, 5 (02) : 173 - 178
  • [6] Pulmonary arterial hypertension and lung transplantation
    Lordan, James L.
    Corris, Paul A.
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2011, 5 (03) : 441 - 454
  • [7] Gaps of evidence in pulmonary arterial hypertension
    Vizza, Carmine Dario
    Ghio, Stefano
    Badagliacca, Roberto
    Manzi, Giovanna
    Scelsi, Laura
    Argiento, Paola
    D'Alto, Michele
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2022, 364 : 119 - 123
  • [8] Pulmonary arterial hypertension, a rare entity
    Eduardo Morales-Blanhir, Jaime
    Eduardo Carmona-Rubio, Andres
    de Jesus Rosas-Romero, Maria
    Vergara de Marquez, Gloria Silene
    Adolfo Arbo-Oze-de-Morvil, Guillermo
    REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION, 2014, 66 (01): : 65 - 78
  • [9] Epoprostenol for the treatment of pulmonary arterial hypertension
    Cristo Ropero, Maria Jose
    Cruz-Utrilla, Alejandro
    Pilar Escribano-Subias, Maria
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2021, 14 (08) : 1005 - 1013
  • [10] Genetics and Pharmacogenomics in Pulmonary Arterial Hypertension
    Smith, Benjamin P.
    Best, D. Hunter
    Elliott, C. Gregory
    HEART FAILURE CLINICS, 2012, 8 (03) : 319 - +